US 12,240,811 B2
N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof
Yinsheng Zhang, Lianyungang (CN); Wangwei Ao, Lianyungang (CN); Yuan Li, Lianyungang (CN); Hui Wang, Lianyungang (CN); Hangzhou Shen, Lianyungang (CN); Jie Ni, Lianyungang (CN); Huan Zhang, Lianyungang (CN); Jie Wu, Lianyungang (CN); Li Zhang, Lianyungang (CN); Kai Cao, Lianyungang (CN); Peng Lu, Lianyungang (CN); Xushi Liu, Lianyungang (CN); Jie Wang, Lianyungang (CN); Tianxiao Zhao, Lianyungang (CN); Xingfeng Ge, Lianyungang (CN); Dandan Lu, Lianyungang (CN); Shuo Chen, Lianyungang (CN); Xueqin Ma, Lianyungang (CN); Wei Shi, Lianyungang (CN); Xiaojin Wang, Lianyungang (CN); and Hongjiang Xu, Lianyungang (CN)
Assigned to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Lianyungang (CN)
Appl. No. 17/425,701
Filed by CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Lianyungang (CN)
PCT Filed Sep. 27, 2019, PCT No. PCT/CN2019/108483
§ 371(c)(1), (2) Date Jul. 23, 2021,
PCT Pub. No. WO2020/151252, PCT Pub. Date Jul. 30, 2020.
Claims priority of application No. 201910073465.2 (CN), filed on Jan. 25, 2019.
Prior Publication US 2022/0185774 A1, Jun. 16, 2022
Int. Cl. C07D 207/34 (2006.01); A61P 31/20 (2006.01)
CPC C07D 207/34 (2013.01) [A61P 31/20 (2018.01)] 4 Claims
 
1. A compound of Formula I or II, a stereoisomer, a tautomer, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry